Rigel Pharmaceuticals Operating Income Over Time
| RIGL Stock | USD 34.26 1.20 3.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Rigel Pharmaceuticals Performance and Rigel Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. Anticipated expansion of Rigel directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Rigel Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 1.086 | Earnings Share 6.19 | Revenue Per Share | Quarterly Revenue Growth 0.256 | Return On Assets |
Investors evaluate Rigel Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rigel Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Rigel Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Rigel Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rigel Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rigel Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Rigel Pharmaceuticals and related stocks such as Gossamer Bio, Kalvista Pharmaceuticals, and Prothena plc Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.7 M) | (149 M) | (186.1 M) | (210.6 M) | (216.1 M) | (218.6 M) | (183.8 M) | (59.9 M) | (53.9 M) | (56.6 M) |
| KALV | (1.8 M) | (1.8 M) | (1.8 M) | (5.2 M) | (11.7 M) | (24.2 M) | (22.3 M) | (18.7 M) | (29.8 M) | (40.5 M) | (57.9 M) | (96.6 M) | (110.9 M) | (140.4 M) | (188 M) | (24.2 M) | (25.4 M) |
| PRTA | (12.2 M) | (29.2 M) | (41.4 M) | (40.4 M) | (6.6 M) | (79.9 M) | (159.5 M) | (155.3 M) | (158.9 M) | (85.7 M) | (112.7 M) | 72 M | (131.6 M) | (191 M) | (154.6 M) | (184.6 M) | (175.3 M) |
| VTYX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (7 M) | (67.1 M) | (113.1 M) | (208 M) | (148.4 M) | (133.6 M) | (140.3 M) |
| FDMT | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (10.4 M) | (50.8 M) | (56.7 M) | (71.3 M) | (110 M) | (112.9 M) | (187.8 M) | (169.1 M) | (160.6 M) |
| AKBA | (8.5 M) | (8.5 M) | (8.5 M) | (15.9 M) | (37.9 M) | (61.5 M) | (136.5 M) | (79.9 M) | (178.1 M) | (286.3 M) | (376.4 M) | (265.3 M) | (80.8 M) | (46.3 M) | (50.5 M) | (45.4 M) | (47.7 M) |
| CRVS | (176 K) | (176 K) | (176 K) | (176 K) | (176 K) | (13.8 M) | (37 M) | (56.5 M) | (49.2 M) | (48.9 M) | (43.8 M) | (38.6 M) | (32.6 M) | (23.4 M) | (27.5 M) | (24.8 M) | (26 M) |
| OLMA | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (4.3 M) | (21.5 M) | (71.5 M) | (107 M) | (105 M) | (142.3 M) | (128 M) | (121.6 M) |
| BCYC | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (16.2 M) | (21.7 M) | (26.3 M) | (52 M) | (65.6 M) | (116.7 M) | (189.9 M) | (209.9 M) | (188.9 M) | (179.4 M) |
| OMER | (7.7 M) | (27.4 M) | (36.9 M) | (50.5 M) | (70 M) | (71.2 M) | (54.3 M) | (43.9 M) | (112.2 M) | (63.4 M) | (156.9 M) | (173.6 M) | (163.4 M) | (164.5 M) | (169.3 M) | (152.3 M) | (144.7 M) |
Rigel Pharmaceuticals and related stocks such as Gossamer Bio, Kalvista Pharmaceuticals, and Prothena plc Operating Income description
Operating Income is the amount of profit realized from Rigel Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Rigel Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Rigel Pharmaceuticals | RIGL |
| Classification | Cancer Fighters |
| Business Address | 611 Gateway Boulevard, |
| Exchange | NASDAQ Exchange |
USD 34.26
Check out Rigel Pharmaceuticals Performance and Rigel Pharmaceuticals Correlation. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Rigel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.